See more : Chinese Energy Holdings Limited (8009.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Atossa Therapeutics, Inc. (ATOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Atossa Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kartoon Studios Inc. (TOON) Income Statement Analysis – Financial Results
- European Residential Real Estate Investment Trust (ERE-UN.TO) Income Statement Analysis – Financial Results
- Workpoint Entertainment Public Company Limited (WORK.BK) Income Statement Analysis – Financial Results
- Parkland Corporation (PKI.TO) Income Statement Analysis – Financial Results
- Hollywood Studios International, Inc. (HYWS) Income Statement Analysis – Financial Results
Atossa Therapeutics, Inc. (ATOS)
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.76K | 525.95K | 632.56K | 481.84K | 1.50K | 0.00 | 0.00 |
| Cost of Revenue | 23.00K | 8.00K | 23.00K | 46.60K | 52.79K | 44.20K | 128.99K | 303.48K | 132.41K | 340.66K | 495.47K | 65.63K | 97.19K | 0.00 | 0.00 |
| Gross Profit | -23.00K | -8.00K | -23.00K | -46.60K | -52.79K | -44.20K | -128.99K | -303.48K | -130.65K | 185.30K | 137.09K | 416.21K | -95.69K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,431.91% | 35.23% | 21.67% | 86.38% | -6,379.33% | 0.00% | 0.00% |
| Research & Development | 17.33M | 15.08M | 9.21M | 6.61M | 6.65M | 4.21M | 2.33M | 770.43K | 2.36M | 2.58M | 1.11M | 1.97K | 0.00 | 120.00K | 21.25K |
| General & Administrative | 14.04M | 12.61M | 11.31M | 8.00M | 10.62M | 7.22M | 4.86M | 6.48M | 8.85M | 8.63M | 8.56M | 5.02M | 3.17M | 882.16K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42M | 1.27M | 1.26M | 466.82K | 160.85K | 12.20K | 0.00 |
| SG&A | 14.04M | 12.61M | 11.31M | 8.00M | 10.62M | 7.22M | 4.86M | 6.48M | 10.27M | 9.90M | 9.82M | 5.49M | 3.33M | 894.36K | 101.61K |
| Other Expenses | 0.00 | -146.00K | -85.00K | 50.80K | 25.65K | 29.30K | 154.00 | 718.97K | 0.00 | 2.01M | 0.00 | 0.00 | 0.00 | 63.64K | 0.00 |
| Operating Expenses | 31.38M | 27.69M | 20.52M | 14.61M | 17.27M | 11.43M | 7.19M | 7.25M | 12.63M | 12.48M | 10.92M | 5.49M | 3.33M | 1.08M | 122.86K |
| Cost & Expenses | 31.38M | 27.69M | 20.52M | 14.61M | 17.27M | 11.43M | 7.19M | 7.25M | 12.76M | 12.82M | 11.42M | 5.55M | 3.43M | 1.08M | 122.86K |
| Interest Income | 4.34M | 877.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 260.00 | 295.00 | 1.22K | 4.91K | 455.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 192.82K | 0.00 | 0.00 | 15.77K | 360.00 | 12.04K | 17.99K | 9.14K | 0.00 |
| Depreciation & Amortization | 23.00K | 8.00K | 23.00K | 46.60K | 52.79K | 44.20K | 128.99K | 303.48K | 272.63K | 564.46K | 472.93K | 130.55K | 15.62K | 455.00 | 0.00 |
| EBITDA | -31.35M | -27.68M | -20.50M | -14.56M | -17.21M | -11.39M | -7.80M | -6.37M | -12.49M | -9.35M | -10.31M | -4.94M | -3.41M | -1.09M | -122.86K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -710,262.91% | -2,336.62% | -1,630.11% | -1,024.66% | -227,243.60% | 0.00% | 0.00% |
| Operating Income | -31.38M | -27.69M | -20.52M | -14.61M | -17.27M | -11.43M | -7.65M | -7.97M | -12.76M | -14.64M | -10.78M | -5.07M | -3.43M | -1.08M | -122.86K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -725,746.19% | -2,783.97% | -1,704.93% | -1,052.01% | -228,612.67% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.28M | 731.00K | -85.00K | -3.22M | 25.65K | 29.30K | -473.41K | 0.00 | 431.00 | -2.49M | -65.00 | -10.82K | -13.08K | -8.68K | 0.00 |
| Income Before Tax | -30.09M | -26.96M | -20.61M | -17.83M | -17.24M | -11.40M | -8.12M | -6.37M | -12.76M | -14.66M | -10.78M | -5.08M | -3.44M | -1.09M | -122.86K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -725,721.67% | -2,786.92% | -1,704.94% | -1,054.26% | -229,484.60% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -731.00K | -213.56K | 3.27M | -119.07K | -29.30K | 742.46K | -1.76M | 3.00M | 2.35M | 65.00 | 10.82K | 13.08K | 250.00 | 0.00 |
| Net Income | -30.09M | -26.23M | -20.61M | -21.10M | -17.24M | -11.40M | -8.12M | -6.37M | -15.76M | -14.66M | -10.78M | -5.08M | -3.44M | -1.09M | -122.86K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -896,491.64% | -2,786.92% | -1,704.94% | -1,054.26% | -229,484.60% | 0.00% | 0.00% |
| EPS | -0.24 | -0.21 | -0.18 | -1.87 | -2.03 | -2.74 | -8.33 | -25.93 | -99.79 | -109.76 | -125.37 | -73.43 | -67.96 | -32.96 | -2.42 |
| EPS Diluted | -0.24 | -0.21 | -0.18 | -1.87 | -2.03 | -2.74 | -8.33 | -25.93 | -99.79 | -109.76 | -125.37 | -73.43 | -67.96 | -32.58 | -2.42 |
| Weighted Avg Shares Out | 126.08M | 126.62M | 116.95M | 11.31M | 8.50M | 4.16M | 974.77K | 245.61K | 157.93K | 133.55K | 86.02K | 69.18K | 50.65K | 32.98K | 50.77K |
| Weighted Avg Shares Out (Dil) | 126.08M | 126.62M | 116.95M | 11.31M | 8.50M | 4.16M | 974.77K | 245.61K | 157.93K | 133.55K | 86.02K | 69.18K | 50.65K | 33.36K | 50.77K |
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
SEATTLE, July 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that on July...
50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
SEATTLE, WA / ACCESSWIRE / July 12, 2023 / One in eight women will be diagnosed with breast cancer during their lifetime. However, breast cancer does not affect all women in the same way, and individual physiology plays a huge...
Maxim upbeat on Atossa Therapeutics after recent updates
Analysts at Maxim Group have reiterated a 'buy' rating on Atossa Therapeutics Inc (NASDAQ:ATOS) shares after the biotech recently announced an enrollment update for its ongoing P2 KarismaEndoxifen study, and also revealed a change of CFO. The P2 trial, which is...
Atossa Therapeutics provides update on Phase 2 breast density trial enrollment
Atossa Therapeutics Inc (NASDAQ:ATOS) announced that 170 patients have been enrolled across its ongoing Phase 2 Karisma-Endoxifen study of its oral formulation of (Z)-endoxifen in premenopausal women with measurable breast density. The company said it expects the trial to...
Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial
SEATTLE, July 10, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that 170 patients...
3 Penny Stocks to Make Your ‘Get Rich' Dreams Come True
When it comes to potentially profitable penny stocks, some can create unimaginable fortunes for patient investors. Others, not so much.
Atossa Therapeutics strikes sponsored research deal with Weill Cornell Medicine for triple negative breast cancer
Atossa Therapeutics Inc (NASDAQ:ATOS), which is developing medicines aimed at oncology and breast cancer, announced a sponsored research agreement with Weill Cornell Medicine to address treatment challenges in triple negative breast cancer (TNBC). The Seattle-based clinical-stage biopharma company said the...
Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer
SEATTLE, July 06, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces a strategic, sponsored research...
Atossa Therapeutics hits 30% enrollment for (Z)-Endoxifen arm of ongoing I-SPY 2 clinical trial
Atossa Therapeutics Inc (NASDAQ:ATOS), which is developing medicines aimed at oncology and breast cancer, revealed that six patients have been dosed with its proprietary selective estrogen receptor modulator (SERM), (Z)-endoxifen, in the ongoing Phase 2 I-SPY 2 clinical trial. The...
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
SEATTLE and SAN FRANCISCO , June 28, 2023 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, and Quantum...
Source: https://incomestatements.info
Category: Stock Reports